The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety
@article{Jones2018ThePA, title={The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety}, author={J. Jones and A. Bisaga and Verena E Metz and J. Manubay and S. Mogali and R. Ciccocioppo and Gabriela Madera and M. Doernberg and S. Comer}, journal={Journal of Psychoactive Drugs}, year={2018}, volume={50}, pages={390 - 401} }
ABSTRACT Possibly through its effects on glia, the peroxisome proliferator-activated gamma receptor (PPARγ) agonist pioglitazone (PIO) has been shown to alter the effects of heroin in preclinical models. Until now, these results have not been assessed in humans. Heroin-dependent participants were randomized to either active (45 mg, n = 14) or placebo (0 mg, n = 16) PIO maintenance for the duration of the three-week study. After stabilization on buprenorphine (8 mg), participants began a two… CONTINUE READING
Topics from this paper
9 Citations
PPARγ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study
- Medicine
- Psychopharmacology
- 2020
- 1
Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence
- Medicine
- Cells
- 2020
- 3
- Highly Influenced
- PDF
Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission
- Medicine
- The Journal of Neuroscience
- 2019
- 7
- PDF
Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples.
- Medicine
- The American journal on addictions
- 2019
Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?
- Medicine
- CNS Drugs
- 2020
- 2
- PDF
Potential of Glial Cell Modulators in the Management of Substance Use Disorders
- Medicine
- CNS Drugs
- 2020
References
SHOWING 1-10 OF 75 REFERENCES
Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential
- Psychology, Medicine
- Pharmacology Biochemistry and Behavior
- 2017
- 17
The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users
- Medicine
- Physiology & Behavior
- 2016
- 15
- PDF
Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.
- Medicine
- Alcoholism, clinical and experimental research
- 2013
- 55
Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents
- Psychology, Medicine
- Psychopharmacology
- 2016
- 22
Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking
- Medicine
- Biological Psychiatry
- 2011
- 100
Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals
- Medicine
- Journal of Pharmacology and Experimental Therapeutics
- 2005
- 46
- PDF
Effect of Chronic Delivery of the Toll-like Receptor 4 Antagonist (+)-Naltrexone on Incubation of Heroin Craving
- Medicine
- Biological Psychiatry
- 2013
- 78
- PDF
PPARc Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission
- Chemistry, Medicine
- Neuropsychopharmacology
- 2015
- 27
- PDF
PPARγ Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission
- Medicine
- Neuropsychopharmacology
- 2015
- 16
The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers
- Psychology, Medicine
- Addiction biology
- 2016
- 38